IXICO is expanding its strategy to accelerate the company’s revenue growth in neurology-focused imaging and biomarker analysis, targeting the market opportunity beyond its current imaging contract research organisation (iCRO) service driven operations. The ‘TechBio’ business model will see IXICO increasingly partner the AI-driven IXI Platform with companies operating in the wider clinical trial management sector and adjacent opportunities. Following the successful 2024 raise, appointment of a ne ....
